What patients ask about long term side effects of psychiatric medications

Patients ask me this question in almost every consultation that stretches past the first few months. What happens if I take this for years? It is an excellent question, and it deserves an honest answer. Psychiatric medications are among the most studied drugs in medicine, and decades of follow up research have given us a real picture of what long term use looks like. That picture is neither a horror story nor a clean bill of health. Here is what the evidence shows for the medications people ask about most.

Weight gain is the side effect people worry about most with antidepressants, and the concern is backed by real data. A population based cohort study in the United Kingdom followed nearly 300,000 people for ten years and found that those prescribed antidepressants were 21 percent more likely to gain at least 5 percent of their starting weight during follow up. The risk was highest during the second and third years of treatment and stayed elevated for about six years. The study could not fully separate the effect of the medication from the effect of depression itself, since depression can change appetite and activity on its own. Still, the signal has been consistent across studies, and certain antidepressants carry more of this risk than others.

Sexual side effects are among the most common reasons people stop antidepressants, and they deserve plain talk. Reduced desire, delayed orgasm, and difficulty reaching orgasm are reported by a meaningful share of people taking SSRIs, and these effects often persist for as long as the medication continues. Another pattern patients describe is emotional blunting, a sense of feeling less of everything, not just sadness but also joy and motivation. A qualitative study from the University of Oxford interviewed people taking SSRIs and found strong evidence that this dulling of emotional experience was a real phenomenon distinct from depression itself, and that it influenced whether people kept taking their medication.

What happens when someone stops is another honest conversation. A systematic review of SSRI discontinuation concluded that stopping can trigger withdrawal symptoms, including dizziness, nausea, anxiety, vivid dreams, and brief electric shock sensations that many patients call brain zaps. Symptoms usually begin within a few days of stopping and last a few weeks, and they can appear even when the dose is tapered gradually. Because these symptoms overlap with a return of depression or anxiety, they are sometimes mistaken for relapse. Fluoxetine, with its very long half life, tends to be the most forgiving of the group. This is not a reason to fear these medications, but it is a reason never to stop them abruptly and to plan any discontinuation with your prescriber.

Bone health is a newer and less certain chapter. A meta analysis of twelve observational studies found that people using SSRIs had a higher risk of fracture, with a pooled odds ratio of 1.69 and the strongest signal for hip and femur fractures. Interestingly, the association was strongest around the start of treatment, which raises the possibility that falls or dizziness early on play a role alongside any direct effect on bone itself. Serotonin receptors exist on bone cells, so a biological mechanism is plausible, but the evidence is observational and cannot prove cause and effect. For older adults on long term treatment, this is a reasonable topic to raise with a prescriber rather than a reason to panic.

SNRIs such as venlafaxine, duloxetine, and desvenlafaxine share most of the SSRI profile, including the weight, sexual, and discontinuation concerns described above. Their distinguishing feature is blood pressure. A meta analysis of 23 randomized trials found that SSRIs did not move blood pressure compared with placebo, while SNRIs produced a modest but statistically significant increase in both systolic and diastolic pressure, on the order of one to two millimeters of mercury. For venlafaxine this effect tends to grow with higher doses, and it is the SNRI most consistently linked to sustained blood pressure rises. People with hypertension or other cardiovascular risk factors who take an SNRI long term should have their blood pressure checked regularly. Discontinuation symptoms with venlafaxine can also be more intense than with most SSRIs, given its short half life.

For ADHD stimulants, the longest running data come from the Multimodal Treatment Study of ADHD, which followed hundreds of children over years. At the three year mark, children who had been consistently treated with stimulants grew about 2.0 centimeters less in height and 2.7 kilograms less in weight than children who remained unmedicated, and the slowdown appeared to level off within the three year window without evidence of rebound. What this means for final adult height is still debated, with different long term analyses reaching different conclusions. In practice this is why pediatric prescribers track growth charts at every visit.

The cardiovascular picture for stimulants is reassuring but not complete. A large study of more than 150,000 adult ADHD medication users found no increased risk of heart attack, sudden cardiac death, or stroke compared with nonusers, though the authors cautioned that they could not fully rule out a modestly elevated risk. Misuse is the other long term concern people raise. Stimulants are controlled substances because they can be misused, and diversion is a real issue, particularly among adolescents and young adults. The long term research on whether prescribed stimulant treatment raises or lowers the risk of later substance problems has produced mixed findings, and this remains one of the genuinely debated areas.

The non stimulant ADHD medications have a different long term profile and, frankly, thinner long term data. Atomoxetine has the most follow up behind it. A four year open label study in adults found that symptom improvement and tolerability were maintained over the full period, with side effects largely matching what would be expected from its noradrenergic action. It can nudge heart rate and blood pressure upward slightly, similar to stimulants though usually to a small degree. Guanfacine extended release, an alpha agonist, tends to lower rather than raise blood pressure and can cause sedation and fatigue. Its longest published follow ups are shorter and smaller than the stimulant literature. Viloxazine is the newest of the group, approved in 2021, and meaningful long term safety data simply do not exist yet. That is not a verdict against it, just a gap worth naming.

Sleep medications are where the gap between short term evidence and long term reality is widest. Zolpidem and the other Z drugs were designed as shorter acting alternatives to benzodiazepines, and trials support their use for weeks. But a comprehensive review of long term treatment with benzodiazepines and related substances found real risks of dependence and withdrawal with extended use, and noted that prescribing often stretches well beyond the intended short course. Tolerance to the sleep benefit can develop while the dependence risk grows, which is an unfavorable trade. Trazodone occupies a different corner. It is one of the most commonly prescribed sleep aids in practice, used off label at lower doses, and it carries a lower risk of dependence than the Z drugs. But rigorous long term studies of trazodone specifically for insomnia are sparse, and it brings its own considerations, including next day grogginess and, rarely, more serious effects such as priapism. For chronic insomnia, the treatment with the strongest long term evidence remains cognitive behavioral therapy for insomnia, not any pill.

So where does this leave the honest answer? Some long term effects are well established. Antidepressants can contribute to weight gain over years, sexual and emotional side effects are common, stopping suddenly can cause withdrawal, and stimulants can slow childhood growth. Some are probable but still being worked out. The fracture signal with SSRIs, the modest blood pressure rises with SNRIs, and the final answer on adult height after childhood stimulant use all sit in this category. And some are genuinely unknown. The decades long effects of newer non stimulants like viloxazine and of chronic trazodone use for sleep are the clearest examples. Uncertainty is not the same as danger, but it is a reason to keep follow up appointments, report new symptoms, and revisit the treatment plan at least once a year rather than refilling on autopilot.

This article is educational only and is not medical advice. Medication decisions belong in a conversation with your own prescriber, who knows your history and can weigh these long term considerations against the very real costs of untreated illness.

Anthony

Sources: Gafoor R et al., BMJ (2018), antidepressant utilisation and incidence of weight gain during 10 years follow up, population based cohort study, PMID 29793997. Price J et al., British Journal of Psychiatry (2009), emotional side effects of selective serotonin reuptake inhibitors, qualitative study, PMID 19721109. Fava GA et al., Psychotherapy and Psychosomatics (2015), withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation, a systematic review, PMID 25721705. Eom CS et al., Journal of Bone and Mineral Research (2012), use of selective serotonin reuptake inhibitors and risk of fracture, a systematic review and meta analysis, PMID 22258738. Zhong Z et al., Neuropsychiatric Disease and Treatment (2017), a meta analysis of effects of selective serotonin reuptake inhibitors on blood pressure in depression treatment, outcomes from placebo and serotonin and noradrenaline reuptake inhibitor controlled trials, PMID 29158677. Swanson JM et al., Journal of the American Academy of Child and Adolescent Psychiatry (2007), effects of stimulant medication on growth rates across 3 years in the MTA follow up, PMID 17667480. Habel LA et al., JAMA (2011), ADHD medications and risk of serious cardiovascular events in young and middle aged adults, PMID 22161946. Adler LA et al., Journal of Attention Disorders (2008), long term open label safety and efficacy of atomoxetine in adults with ADHD, final report of a 4 year study, PMID 18448861. Janhsen K et al., Deutsches Arzteblatt International (2015), the problems of long term treatment with benzodiazepines and related substances, prescribing practice epidemiology and the treatment of withdrawal, PMID 25613443.